[go: up one dir, main page]

WO2005092352A1 - Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques - Google Patents

Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques Download PDF

Info

Publication number
WO2005092352A1
WO2005092352A1 PCT/CN2004/000257 CN2004000257W WO2005092352A1 WO 2005092352 A1 WO2005092352 A1 WO 2005092352A1 CN 2004000257 W CN2004000257 W CN 2004000257W WO 2005092352 A1 WO2005092352 A1 WO 2005092352A1
Authority
WO
WIPO (PCT)
Prior art keywords
chinese medicine
traditional chinese
liposome
extract
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2004/000257
Other languages
English (en)
Chinese (zh)
Inventor
Jianzhong Zhu
Zupei Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CN2004/000257 priority Critical patent/WO2005092352A1/fr
Publication of WO2005092352A1 publication Critical patent/WO2005092352A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the traditional Chinese medicine liposome can be used for the treatment of viral hepatitis B chronic hepatitis, chronic active hepatitis, acute hepatitis, steatohepatitis, alcoholic hepatitis, toxic hepatitis, and initial liver cirrhosis.
  • the two groups were administered continuously for 8 weeks as a course of treatment.
  • the youngest patients were 18 years old and the highest 65 years old. There were 28 males and 12 females.
  • Patients who had used enzyme-lowering drugs within 45 days before treatment were not observed.
  • routine urine ALT, AST. SB, GGT, ALP. A / G, BuN, and testing were performed to record changes in clinical symptoms and signs.
  • the percentage of the total weight of the active ingredients of traditional Chinese medicine and the total weight of lecithin (including egg yolks and soybeans) and other corresponding medical accessories is: (35: 65)% of standard formulated lecithin (containing egg yolks, soybeans) ) And other corresponding medical accessories.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un liposome de médecine chinoise pour le traitement de l'hépatite B virale et la prévention et le traitement de la fibration des cellules hépatiques, ainsi que son procédé de préparation. Ledit liposome est un liposome multiphase formé de 34-48 % en poids d'extrait de composant actif de médecine chinoise, et 66-52 % en poids de lécithine et de substance médicinale auxiliaire. Le composant actif comprend un tubercule de curcuma, des baies de schisandra, de la pivoine officinale blanche et de la réglisse. On enrobe dans un liposome un médicament de médecine chinoise régulant le système immunitaire et protégeant le foie, pour le traitement de l'hépatite B virale chronique et pour la prévention et le traitement de la fibration des cellules hépatiques. Ainsi, on combine les avantages du liposome et les caractéristiques de la médecine chinoise. L'effet thérapeutique du traitement de l'hépatite B virale ainsi que de la prévention et du traitement de la fibration des cellules hépatiques est fiable et facile à obtenir.
PCT/CN2004/000257 2004-03-26 2004-03-26 Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques Ceased WO2005092352A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000257 WO2005092352A1 (fr) 2004-03-26 2004-03-26 Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000257 WO2005092352A1 (fr) 2004-03-26 2004-03-26 Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques

Publications (1)

Publication Number Publication Date
WO2005092352A1 true WO2005092352A1 (fr) 2005-10-06

Family

ID=35055980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/000257 Ceased WO2005092352A1 (fr) 2004-03-26 2004-03-26 Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques

Country Status (1)

Country Link
WO (1) WO2005092352A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244281A (zh) * 2021-06-09 2021-08-13 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用
US11197834B2 (en) 2017-07-11 2021-12-14 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
CN114767748A (zh) * 2022-05-18 2022-07-22 中山大学 刺梨或其提取物在制备防治肝纤维化的药物或功能食品中的应用
US11786484B2 (en) 2018-07-11 2023-10-17 Aquanova Ag Xanthohumol solubilizate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1032295A (zh) * 1988-02-22 1989-04-12 黑龙江省中医学院中药厂 利肝隆的制造方法
JPH03197408A (ja) * 1989-12-27 1991-08-28 Kobayashi Kose Co Ltd リポソーム及びリン脂質分散液の安定化法
CN1075422A (zh) * 1992-12-15 1993-08-25 吉林省敦化市制药厂 一种治疗肝炎的药物
WO1997002831A1 (fr) * 1995-07-10 1997-01-30 Cathay Herbal Laboratories Pty. Ltd. Compositions a base d'herbes contre des dereglements hepatiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1032295A (zh) * 1988-02-22 1989-04-12 黑龙江省中医学院中药厂 利肝隆的制造方法
JPH03197408A (ja) * 1989-12-27 1991-08-28 Kobayashi Kose Co Ltd リポソーム及びリン脂質分散液の安定化法
CN1075422A (zh) * 1992-12-15 1993-08-25 吉林省敦化市制药厂 一种治疗肝炎的药物
WO1997002831A1 (fr) * 1995-07-10 1997-01-30 Cathay Herbal Laboratories Pty. Ltd. Compositions a base d'herbes contre des dereglements hepatiques

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197834B2 (en) 2017-07-11 2021-12-14 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US11344509B2 (en) 2017-07-11 2022-05-31 Aquanova Ag Solubilizate with curcumin and boswellia and xanthohumol
US11931322B2 (en) 2017-07-11 2024-03-19 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US12144784B2 (en) 2017-07-11 2024-11-19 Aquanova Ag Solubilizate with curcumin and optionally at least one other active substance
US11786484B2 (en) 2018-07-11 2023-10-17 Aquanova Ag Xanthohumol solubilizate
CN113244281A (zh) * 2021-06-09 2021-08-13 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用
CN113244281B (zh) * 2021-06-09 2022-11-01 贵州医科大学 黄水枝醇提物在制备治疗或保护、调节肝纤维化疾病药物中的应用
CN114767748A (zh) * 2022-05-18 2022-07-22 中山大学 刺梨或其提取物在制备防治肝纤维化的药物或功能食品中的应用
CN114767748B (zh) * 2022-05-18 2023-11-10 中山大学 刺梨或其提取物在制备防治肝纤维化的药物中的应用

Similar Documents

Publication Publication Date Title
CN101590168B (zh) 一种用于治疗痛风的中药组合物及其制备方法
CN101590184B (zh) 一种用于治疗痛风的中药组合物及其制备方法
WO2009149585A1 (fr) Compositions destinées à réduire le niveau de glucose dans le sang, et utilisations de celles-ci
CN102846667B (zh) 一种经低温干燥制备纳米美洲大蠊的制备方法
CN103041341B (zh) 用于治疗结核性渗出性胸膜炎的中药组合物及其制备方法
CN102293928A (zh) 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用
CN106620475B (zh) 一种防治糖尿病认知障碍的中药组合物及制备方法
WO2005092352A1 (fr) Procede de production utilisations de preparation liposomique de medecine chinoise pour le traitement de l'hepatite b virale et pour la prevention et le traitement de la fibration des cellules hepatiques
CN102091285B (zh) 一种清热醒脑的药物制剂及制备方法和用途
CN101829188B (zh) 一种治疗泌尿系感染和结石病的药物
CN101590169A (zh) 一种用于治疗痛风的中药组合物及其制备方法
CN101590166B (zh) 一种用于治疗痛风的中药组合物及其制备方法
CN109464517A (zh) 清热解毒儿科外用按摩软膏配方、制备软膏的方法及应用
CN100536867C (zh) 治疗肝功能损害的复方中药制剂及其制备
CN102205109B (zh) 一种治疗风湿病的中药组合物及其应用
CN1283308C (zh) 一种治疗病毒性乙型肝炎、防治肝细胞纤维化的中药脂质体及制备方法
CN104288670B (zh) 一种治疗或/和预防阿尔茨海默病药物组合物及其制备方法和用途
CN116785385B (zh) 一种用于防治病毒性呼吸道疾病的中药组合物
CN107625863B (zh) 治疗风湿骨病的复方中药软胶囊及其制备方法
CN106267134A (zh) 一种消炎镇痛中药组合物及其制备方法
CN117281740A (zh) 一种保肝护肝的中药组合物及其制备方法和应用
CN105853582A (zh) 一种含有艾叶的治疗胆石症的药物制剂及其制备方法
CN105267659A (zh) 一种治疗胃火炽盛型牙松齿动的药粉
CN111905041A (zh) 汽疗法治疗高脂血症的中药组合物及其制备方法
CN110384779A (zh) 一种牙疼快速止疼膏外用药物及其制作方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1)EPC

122 Ep: pct application non-entry in european phase

Ref document number: 04723500

Country of ref document: EP

Kind code of ref document: A1